Wang, Chuheng Duan, Linan Zhao, Yao Wang, Yubo Li, Yunqian
Published in
World neurosurgery
Glioma is the most common malignant brain tumor in neurosurgery. Bevacizumab (BEV) is a monoclonal antibody that inhibits tumors by inhibiting vascular endothelial growth factor and reducing tumor angiogenesis. To evaluate the efficacy and safety of BEV combined with temozolomide (TMZ) in glioma, we performed a meta-analysis. PubMed, Embase, The Co...
Roth, Patrick Gorlia, Thierry Reijneveld, Jaap C de Vos, Filip Idbaih, Ahmed Frenel, Jean-Sébastien Le Rhun, Emilie Sepulveda, Juan Manuel Perry, James Masucci, G Laura
...
BackgroundStandard treatment for patients with newly diagnosed glioblastoma includes surgery, radiotherapy (RT), and temozolomide (TMZ) chemotherapy (TMZ/RT→TMZ). The proteasome has long been considered a promising therapeutic target because of its role as a central biological hub in tumor cells. Marizomib is a novel pan-proteasome inhibitor that c...
Roth, Patrick Gorlia, Thierry Reijneveld, Jaap C de Vos, Filip Idbaih, Ahmed Frenel, Jean-Sébastien Le Rhun, Emilie Sepulveda, Juan Manuel Perry, James Masucci, G Laura
...
peer reviewed / [en] BACKGROUND: Standard treatment for patients with newly diagnosed glioblastoma includes surgery, radiotherapy (RT), and temozolomide (TMZ) chemotherapy (TMZ/RT→TMZ). The proteasome has long been considered a promising therapeutic target because of its role as a central biological hub in tumor cells. Marizomib is a novel pan-prot...
Hacioglu, Ceyhan Tuncer, Cengiz
Published in
Biological trace element research
Glioblastoma (GBM) is a common and highly lethal form of brain cancer. Temozolomide (TMZ) is the primary chemotherapy used for GBM, but it has limited effectiveness, with about half of the patients developing resistance. Iron regulatory proteins (IRPs) modulate genes involved in iron metabolism, while the nuclear receptor coactivator 4 (NCOA4) cont...
He, Ling Ioannidis, Angeliki Hoffman, Carter J Arambula, Evelyn Joshi, Purva Whitelegge, Julian Liau, Linda M Kornblum, Harley I Pajonk, Frank
Glioblastoma (GBM) is the deadliest adult brain cancer. Under the current standard of care, almost all patients succumb to the disease and novel treatments are urgently needed. Recognizing that GBMs are addicted to cholesterol, past clinical trials have repurposed statins against GBM but failed. The purpose of this study was to test whether treatme...
Rydén, Viktoria El-Naggar, Ali Inan Koliadi, Anthoula Ladjevardi, Cecilia Olsson Digkas, Evangelos Valachis, Antonios Ullenhag, Gustav J
Published in
Pigment cell & melanoma research
Dacarbazine (DTIC) and its oral counterpart temozolomide (TMZ) have been the most used agents in advanced malignant melanoma (MM) patients and they are still used routinely. The preferred first line treatment, immune checkpoint inhibitors (CPIs) might shape the tumor and the tumor microenvironment, possibly affecting the response to subsequent ther...
Liang, Bao-Bao Wang, Yu-Hong Huang, Jing-Jing Lin, Shuai Mao, Guo-Chao Zhou, Zhang-Jian Yan, Wan-Jun Shan, Chang-You Wu, Hui-Zi Etcheverry, Amandine
...
Published in
CNS neuroscience & therapeutics
To identify potent DNA methylation candidates that could predict response to temozolomide (TMZ) in glioblastomas (GBMs) that do not have glioma-CpGs island methylator phenotype (G-CIMP) but have an unmethylated promoter of O-6-methylguanine-DNA methyltransferase (unMGMT). The discovery-validation approach was planned incorporating a series of G-CIM...
Abband, Hedieh Dabirian, Sara Jafari, Adele Nasiri, Mehran Nasiri, Ebrahim
Published in
Anatomy & cell biology
Glioblastoma is the most common primary malignant brain tumor in adults. Temozolomide (TMZ) is an FDA-approved drug used to treat this type of cancer. Cinnamaldehyde (CIN) is a derivative of cinnamon extract and makes up 99% of it. The aim of this study was to investigate the in vitro combined effect of CIN and TMZ on human glioblastoma multiforme ...
Meng, Jiao Qian, Wei Yang, Zhenkun Gong, Lingli Xu, Daxing Huang, Hongbo Jiang, Xinyi Pu, Zhening Yin, Ying Zou, Jian
...
Published in
BMC Cancer
Background Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer, and chemoresistance poses a significant challenge to the survival and prognosis of GBM. Although numerous regulatory mechanisms that contribute to chemoresistance have been identified, many questions remain unanswered. This study aims to identify the mechanism of ...
Abdoli Shadbad, Mahdi Nejadi Orang, Fatemeh Baradaran, Behzad
Published in
European Journal of Medical Research
Background Glioblastoma multiform (GBM) is among the commonly diagnosed brain malignancies with poor prognosis. CD133 has been introduced as an oncogene in various cancers, like GBM. This study aimed to investigate the significance of CD133 in GBM development using in silico and in vitro techniques. Method The TCGA-GBM database was analyzed for the...
